| Date Filed | Type | Description |
| 10/11/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 10/03/2023 |
S-3/A
| Form S-3/A - Registration statement under Securities Act of 1933: [Amend] |
| 08/08/2023 |
8-K
| Quarterly results |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 06/06/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"ESSA Pharma Appoints Lauren Merendino to its Board of Directors South San Francisco, California and Vancouver, Canada, June 6, 2023 - ESSA Pharma Inc. , a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the appointment of Lauren Merendino, M.B.A., to its Board of Directors. Ms. Merendino is a leading biopharmaceutical executive who brings over 25 years of commercial experience spanning 20+ disease states, including 15 years of leadership for oncology-specific portfolios. “Lauren’ s cross-functional expertise in guiding products through all stages of commercial development adds a valuable perspective that complements the skillset of our Board of Directors,” stated Richard M. Glickman, L.L.D. , Chairman of ESSA..." |
|
| 05/09/2023 |
8-K
| Quarterly results |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 03/10/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 02/14/2023 |
SC 13G/A
| PFM Health Sciences, LP reports a 8.7% stake in ESSA Pharma Inc. |
| 02/14/2023 |
SC 13G/A
| Soleus Capital, LLC reports a 8.8% stake in ESSA Pharma Inc. |
| 02/14/2023 |
SC 13G/A
| Avidity Partners Management LP reports a 4.2% stake in ESSA Pharma Inc. |
| 02/14/2023 |
SC 13G/A
| EVENTIDE ASSET MANAGEMENT, LLC reports a 0% stake in Essa Pharma Inc. |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/07/2023 |
8-K
| Quarterly results |
| 02/07/2023 |
10-Q
| Quarterly Report for the period ended December 31, 2022 |
| 01/24/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 12/13/2022 |
8-K
| Quarterly results |
| 12/13/2022 |
10-K
| Annual Report for the period ended September 30, 2022 |
| 11/10/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 10/31/2022 |
8-K
| Quarterly results |
| 10/27/2022 |
SC 13G
| Avidity Partners Management LP reports a 8.5% stake in ESSA Pharma Inc. |
| 10/26/2022 |
8-K
| Quarterly results |
| 09/13/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"ESSA Pharma Appoints Philip Kantoff to its Board of Directors South San Francisco, California and Vancouver, Canada, September 13, 2022 - ESSA Pharma Inc. , a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the appointment of Philip Kantoff, M.D., to its Board of Directors. Dr. Kantoff brings invaluable insight and experience to ESSA as a renowned medical oncologist and leader in the clinical development of new prostate cancer treatments. “Phil’ s breadth and quality of accomplishments are unmatched, and we are honored to welcome him to ESSA’ s Board of Directors,” stated Richard M. Glickman, L.L.D. , Chairman of ESSA's Board of Directors. “We are eager to leverage Phil’ s admirable expertise in prostate canc..." |
|
| 08/04/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/04/2022 |
8-K
| Quarterly results |
| 07/12/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 06/27/2022 |
8-K
| Quarterly results |
| 05/10/2022 |
8-K
| Quarterly results |
| 05/10/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 03/10/2022 |
8-K
| Quarterly results |
| 02/14/2022 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 10% stake in ESSA Pharma Inc. |
| 02/14/2022 |
SC 13G/A
| EVENTIDE ASSET MANAGEMENT, LLC reports a 7.5% stake in ESSA Pharma Inc. |
| 02/14/2022 |
SC 13G/A
| RTW INVESTMENTS, LP reports a 6% stake in ESSA Pharma Inc. |
|